Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17A | Q9UEE5 | 4/20 | 0.47 |
| ▸ | JAK2 | O60674 | 2/20 | 0.47 |
| ▸ | MYLK4 | Q86YV6 | 3/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | MAP3K12 | Q12852 | 11/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4277985 | 1.00 | STK17A (0.47) | STK17AJAK2MYLK4CLK4MAP3K12 | |
| SCHEMBL4279074 | 0.91 | ZAP70 (0.54) | STK17AJAK2MYLK4CLK4CDK1 | |
| SCHEMBL4281318 | 0.91 | ZAP70 (0.54) | STK17AJAK2MYLK4CLK4CDK1 | |
| SCHEMBL4280710 | 0.88 | ZAP70 (0.51) | STK17AJAK2MYLK4CLK4MAP3K12 | |
| SCHEMBL4290873 | 0.88 | ZAP70 (0.51) | STK17AJAK2MYLK4CLK4MAP3K12 | |
| SCHEMBL4288821 | 0.87 | JAK2 (0.49) | STK17AJAK2MYLK4MAPTCDK1 | |
| SCHEMBL4277470 | 0.87 | JAK2 (0.49) | STK17AJAK2MYLK4MAPTCDK1 | |
| SCHEMBL4286106 | 0.84 | STK17A (0.48) | STK17AMYLK4CLK4MAP3K12 | |
| SCHEMBL4276690 | 0.84 | STK17A (0.48) | STK17AMYLK4CLK4MAP3K12 | |
| SCHEMBL4283925 | 0.82 | STK17A (0.46) | STK17AJAK2MYLK4CLK4MAP3K12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017007658-A1 | A COMBINATION FOR IMMUNE MEDIATED CANCER TREATMENT | RIGEL PHARMACEUTICALS, INC. (US) | 2017-01-12 | — | — | WO | claimed |
| US-9624229-B2 | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases | RIGEL PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| WO-2017007658-A1 | A COMBINATION FOR IMMUNE MEDIATED CANCER TREATMENT | RIGEL PHARMACEUTICALS, INC. (US) | 2017-01-12 | — | — | WO | disclosed |
| EP-2265607-B1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | RIGEL PHARMACEUTICALS INC (US) | 2016-12-14 | — | — | EP | disclosed |
| US-20140213585-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | RIGEL PHARMACEUTICALS, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-8735418-B2 | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases | RIGEL PHARMACEUTICALS, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| WO-2013173506-A2 | METHOD OF TREATING MUSCULAR DEGRADATION | RIGEL PHARMACEUTICALS, INC. (US) | 2013-11-21 | — | — | WO | disclosed |
| US-20130018041-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | RIGEL PHARMACEUTICAL, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-8309566-B2 | Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases | RIGEL PHARMACEUTICALS, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20090258864-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | RIGEL PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213585-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | JAK2, JAK1, JAK3 | STK17A 247/4885JAK2 1/4885MYLK4 1575/4885 |
| US-20130018041-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | JAK2, JAK1, JAK3 | STK17A 213/4885JAK2 1/4885MYLK4 1855/4885 |
| US-20090258864-A1 | PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES | JAK2, JAK1, JAK3 | STK17A 229/4885JAK2 1/4885MYLK4 1872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.